Login

Healthcare

00:10:00
Pharmaceutical solutions at every stage|Paul McDonald,Chief Executive Officer,
00:10:00
Our naturally safe ingredients deliver pure nutritional performance and clinically-proven health benefits|Dr. Bomi Framroze,Chief Scientific Officer,Hofseth Biocare
00:10:00
we are focused on discovering developing and commercializing novel gene and cell therapies and vaccines|Jon Lieber, Chief Financial Officer,Histogenics Corp
00:10:00
Develop disease modifying therapies to stop or reverse the progression of neurodegenerative diseases|ANTTI VUOLANTO,Chief Executive Officer,Herantis Pharma Oyj
00:10:00
We are Advancing Immunology Solutions for a Better Future|Thomas K Equels, Chief Executive Officer,Hemispherx BioPharma
00:10:00
Revolutionizing Neurodegenerative Disease Treatment| Dr. Maria Maccecchini, CEO, Annovis Bio Inc.
00:10:00
New development partnership aims to revolutionize breast cancer diagnosis|Andrew Newland, CEO, Angle PLC.
00:10:00
Navigating Innovation and Customer Care in the Hearing Care Sector|Enrico Vita , CEO, Amplifon Spa .
00:10:00
Next Target for Antibe Therapeutics' Proprietary Hydrogen Sulfide Platform: Inflammatory Bowel Disease (IBD)|Dan Legault, CEO, Antibe Therapeutics Inc.
00:10:00
Proprietary Nano Polymer Technology Poised to Revolutionize Clean Energy and Life Sciences Sectors, Targeting First Revenues|David Radford, CEO, Anteotech Ltd.
00:10:00
Revolutionizing Worker Safety and Efficiency Through Smart Wearables: An Innovative Partnership |Neil Salmon, CEO, Anpario PLC.
00:10:00
Navigating Ambu's Revival: Britt Meelby Jensen Shares Insights on Strategic Execution and Capital Optimization in the Life Science Industry |Britt Meelby Jensen, CEO,Ambu A/S.
00:10:00
Revolutionizing Cancer Screening: A Breakthrough in Liquid Biopsy Technology Unveiled| Chris Yu, CEO, AnPac Bio-Medical Science Co Ltd.
00:10:00
Advancements in Neurodegenerative Disease Treatment Research: Clinical Trials Update| Dr. Maria Maccecchini, CEO, Annovis Bio Inc.
00:10:00
Exploring the Potential of a Revolutionary Cancer Vaccine | Amit Kumar, CEO, Anixa Biosciences Inc .
00:10:00
New Pharma Services Division Secures $1.2M Follow-On Contract for Innovative Cancer Patient Trial Assessment Approach |Andrew Newland, CEO, Angle PLC.

© 2026 Nehu